4 days ago
Charles River Laboratories (NYSE:CRL) on Wednesday announced significant plans to divest parts of its business.
Charles River agreed to divest its CDMO and Cell Solutions businesses, along with certain European Discovery Services assets.
Planned Divestiture Of CDMO and Cell Solutions Businesses
Charles River to sell its contract development and manufacturing organization (CDMO) and Cell Solutions businesses to GI Partners, an alternatives investment firm, primarily for future, contingent performance-based payments.
The CDMO business provides services related to the production of advanced therapies for gene-modified cell therapies, as well as gene therapies, including viral vectors and plasmid DNA, and the Cell Solutions business provides human-derived cellular materials used in the development and production of cell therapies.
The company will offload its CDMO sites in Tennessee, Maryland, and the United Kingdom and its Cell Solutions site in California.
The businesses generated combined annual revenue of $143 million in 2025, including $117 million in the Manufacturing Solutions segment and ...
